Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

Maron, Martin S.; Masri, Ahmad; Choudhury, Lubna; Olivotto, Iacopo; Saberi, Sara; Wang, Andrew; García‐Pavía, Pablo; Lakdawala, Neal K.; Nagueh, Sherif F.; Rader, Florian; Tower‐Rader, Albree; Turer, Aslan T.; Coats, Caroline; Fifer, Michael A.; Owens, Anjali; Solomon, Scott D.; Watkins, Hugh; Barriales‐Villa, Roberto; Kramer, Christopher M.; Wong, Timothy C.; Paige, Sharon L.; Heitner, Stephen B.; Kupfer, Stuart; Malik, Fady I.; Meng, Lisa; Wohltman, Amy; Abraham, Theodore P.

doi:10.1016/j.jacc.2022.10.020

articleJournal of the American College of CardiologyJan 1, 2023HYBRID OA

Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

MSMartin S. Maron AMAhmad Masri LCLubna Choudhury IOIacopo Olivotto SSSara Saberi

Lahey Hospital and Medical Center · Lahey Medical Center · +23 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Background

Left ventricular outflow tract (LVOT) obstruction is a major determinant of heart failure symptoms in obstructive hypertrophic cardiomyopathy (oHCM). Aficamten, a next-in-class cardiac myosin inhibitor, may lower gradients and improve symptoms in these patients.

Objectives

This study aims to evaluate the safety and efficacy of aficamten in patients with oHCM.

Citation impact

191

total citations

FWCI: 40.42
Percentile: 100%
References: 20

Citations per year

Authors

27

Topics & keywords

Topics

Keywords

Medicine
Placebo
Ejection fraction
Heart failure
Cardiology
Internal medicine
Hypertrophic cardiomyopathy
Natriuretic peptide

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.